Current Status and Clinical Developments in Lung Cancer: What to Expect from Emerging Drugs? (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 July 2026 | Viewed by 630
Special Issue Editor
Interests: epigenetic modulation in solid tumors; lung cancer; next generation technologies in molecular biology; predictive oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous one, entitled "Current Status and Clinical Developments in Lung Cancer: What to Expect from Emerging Drugs?”.
Lung cancer, small-cell lung cancer and non-small cell lung cancer are the leading causes of cancer-related death. Most of the time, symptoms appear late; thus, the diagnosis of patients with lung cancer occurs at an advanced stage. The treatment of patients with this disease includes multidisciplinary approaches that are based on surgical practice, such as chemotherapy, radiotherapy, targeted therapies, and immunotherapy, which largely improve patients’ quality of life and survival rates.
For this reason, this Special Issue welcomes studies on innovative treatments, as well as immunotherapy drugs and molecular targeted therapies, which could enhance our understanding of the molecular biology of lung cancer in the era of personalized medicine. Submission focusing on diagnostic and therapeutic technologies and rational drug design are also encouraged.
Dr. Federico Pio Fabrizio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- immunotherapy
- immune checkpoint inhibitors (ICIs)
- target therapy
- tyrosine kinase inhibitors (TKIs)
- cancer biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
